XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated and Combined Statements of Changes in Stockholders’ (Deficit) Equity (Unaudited) - USD ($)
Common Stock
Previously Reported
Common Stock
Retroactive Application of Recapitalization
Common Stock
Additional Paid-in Capital
Previously Reported
Additional Paid-in Capital
Retroactive Application of Recapitalization
Additional Paid-in Capital
Accumulated Deficit
Previously Reported
Accumulated Deficit
Retroactive Application of Recapitalization
Accumulated Deficit
Stock Subscription Receivable
Previously Reported
Stock Subscription Receivable
Retroactive Application of Recapitalization
Stock Subscription Receivable
Previously Reported
Retroactive Application of Recapitalization
Total
Balance at Dec. 31, 2023 $ 6,980 $ 6,980 $ 28,857,965 $ (6,980) $ 28,850,985 $ (25,445,506) $ (25,445,506) $ 3,412,459 $ 3,412,459
Balance (in Shares) at Dec. 31, 2023   1,396,000 1,396,000                        
Capital contributions from related party         487,273             487,273
Issuance of common stock upon consummation of the Merger     $ 600     (27,888,519)             (27,887,919)
Issuance of common stock upon consummation of the Merger (in Shares)     120,093                        
Conversion of convertible notes into common stock     $ 596     3,174,404             3,175,000
Conversion of convertible notes into common stock (in Shares)     119,245                        
Stock subscription receivable                 (80,241)     (80,241)
Earnout Arrangement         63,600,000     (63,600,000)        
Contingent consideration         906,000     (906,000)        
Convertible note – stock issuance loss       2,769,719         2,769,719
Private Placement     $ 513     8,931,484             8,931,997
Private Placement (in Shares)     102,667                        
Issuance costs in connection with the Private Placement         (262,064)             (262,064)
Stock-based compensation         1,359,000             1,359,000
Net income (loss)       (29,766,263)   (32,535,982)     (29,766,263)   (32,535,982)
Balance at Mar. 31, 2024     $ 8,689 79,158,563   81,928,282 (119,717,769)   (122,487,488)     (80,241) (40,630,758)   (40,630,758)
Balance (in Shares) at Mar. 31, 2024     1,738,005                        
Balance at Dec. 31, 2023 $ 6,980 $ 6,980 $ 28,857,965 $ (6,980) 28,850,985 $ (25,445,506) (25,445,506) $ 3,412,459 3,412,459
Balance (in Shares) at Dec. 31, 2023   1,396,000 1,396,000                        
Net income (loss)                             25,929,003
Balance at Dec. 31, 2024     $ 13,169     93,045,581     (115,880,509)     (80,241)     (22,902,000)
Balance (in Shares) at Dec. 31, 2024     2,633,956                        
Shares issued from exercise of Series A Warrants     $ 74     241,472             241,546
Shares issued from exercise of Series A Warrants (in Shares)     14,755                        
Conversion of convertible notes into common stock     $ 339     527,161             527,500
Conversion of convertible notes into common stock (in Shares)     67,895                        
Shares issued to consultants     $ 1     670             671
Shares issued to consultants (in Shares)     100                        
Reverse stock split     $ (13,311)     13,311            
Stock-based compensation         754,361             754,361
Net income (loss)             9,194,630         9,194,630
Balance at Mar. 31, 2025     $ 272     $ 94,582,556     $ (106,685,879)     $ (80,241)     $ (12,183,292)
Balance (in Shares) at Mar. 31, 2025     2,716,706